Baseline Predictors of Response to Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib Plus Dasatinib and/or Nilotinib.

被引：0
|
作者：
Cortes, Jorge E. [1 ]
Khoury, H. Jean [2 ]
Lipton, Jeff H. [3 ]
Gambacorti-Passerini, Carlo [4 ]
Bruemmendorf, Tim H. [5 ]
Kim, Dong-Wook [6 ]
Leip, Eric [7 ]
Kelly, Virginia [7 ]
Besson, Nadine [8 ]
Turnbull, Kathleen [7 ]
Kantarjian, Hagop M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Univ Milano Bicocca, Monza, Italy
[5] Rhein Westfal TH Aachen, Univ Klinikum Aachen, Aachen, Germany
[6] Seoul St Marys Hosp, Seoul, South Korea
[7] Pfizer Inc, Cambridge, MA USA
[8] Pfizer Global Res & Dev, Paris, France
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.2793.2793
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2793
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
    Cortes, Jorge E.
    Khoury, Hanna J.
    Kantarjian, Hagop M.
    Lipton, Jeff H.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Matczak, Ewa
    Leip, Eric
    Noonan, Kay
    Bruemmendorf, Tim H.
    Gambacorti-Passerini, Carlo
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) : 1206 - 1214
  • [2] CLINICAL EXPERIENCE OF BOSUTINIB UNDER COMPASIONATE USE PROGRAM IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO IMATINIB, DASATINIB AND NILOTINIB
    Garcia-Gutierrez, V.
    Maestro, B.
    Cervantes, F.
    Lopez Lorenzo, J. L.
    Martin Mateos, M. L.
    Alvarez, A.
    Iglesias Perez, A.
    Romo Collado, A.
    Fernandez Fernandez, A.
    Bautista, G.
    Portero, A.
    Cuevas, B.
    Ruiz, C.
    Amutio, E.
    Del Orbe, R. D. A.
    Romero, E.
    Ortega, F.
    Mata, I.
    Tallon, J.
    Garcia Garay, M. D. C.
    Ramirez Sanchez, M. J.
    de las Heras, N.
    Giraldo, P.
    Bobillo, S.
    Steegmann, J. L.
    HAEMATOLOGICA, 2014, 99 : 337 - 338
  • [3] Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
    Khoury, H. Jean
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Gambacorti-Passerini, Carlo
    Baccarani, Michele
    Kim, Dong-Wook
    Zaritskey, Andrey
    Countouriotis, Athena
    Besson, Nadine
    Leip, Eric
    Kelly, Virginia
    Bruemmendorf, Tim H.
    BLOOD, 2012, 119 (15) : 3403 - 3412
  • [4] DASATINIB, HIGH-DOSE IMATINIB AND NILOTINIB IN CHINESE PATIENTS WITH CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB-RESISTANCE OR -INTOLERANCE: AN ECONOMIC EVALUATION
    Wu, B.
    VALUE IN HEALTH, 2015, 18 (07) : A460 - A460
  • [5] Prediction of outcomes in patients with Ph plus chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
    Jabbour, E.
    le Coutre, P. D.
    Cortes, J.
    Giles, F.
    Bhalla, K. N.
    Pinilla-Ibarz, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Hochhaus, A.
    Hughes, T. P.
    Saglio, G.
    Radich, J. P.
    Kim, D-W
    Martinelli, G.
    Reynolds, J.
    Woodman, R. C.
    Baccarani, M.
    Kantarjian, H. M.
    LEUKEMIA, 2013, 27 (04) : 907 - 913
  • [6] BOSUTINIB FOR THIRD-LINE TREATMENT OF CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) FOLLOWING RESISTANCE OR INTOLERANCE TO IMATINIB (IM) AND DASATINIB (D)
    Gambacorti-Passerini, C.
    Cortes, J.
    Zaritskey, A.
    Bullorsky, E.
    Navarro, J.
    Khoury, H.
    Besson, N.
    McMullan, T.
    Arkin, S.
    Bruemmendorf, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 57 - 58
  • [7] Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Resistance Or Intolerance To Imatinib: 48-Month Update
    Bruemmendorf, Tim H.
    Cortes, Jorge E.
    Khoury, H. Jean
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Conlan, Maureen G.
    Leip, Eric
    Turnbull, Kathleen
    Gambacorti-Passerini, Carlo
    Lipton, Jeff H.
    BLOOD, 2013, 122 (21)
  • [8] PREDICTORS OF STABLE DEEP MOLECULAR RESPONSE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH DASATINIB OR NILOTINIB AFTER IMATINIB FAILURE
    Bonifacio, M.
    Binotto, G.
    Tiribelli, M.
    Scaffidi, L.
    Iurlo, A.
    Cibien, F.
    Maino, E.
    Guella, A.
    Festini, G.
    Minotto, C.
    De Biasi, E.
    Frison, L.
    De Marchi, F.
    Medeot, M.
    Bucelli, C.
    Calistri, E.
    Stulle, M.
    Gherlinzoni, F.
    Cortelezzi, A.
    Fanin, R.
    Semenzato, G.
    Krampera, M.
    Pizzolo, G.
    Ambrosetti, A.
    HAEMATOLOGICA, 2016, 101 : S74 - S74
  • [9] Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update
    Khoury, H. Jean
    Gambacorti-Passerini, Carlo
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Marin, David
    Dorlhiac-Llacer, Pedro E.
    Zaritskey, Andrey
    Navarro, Juan
    Bullorsky, Eduardo O.
    Assouline, Sarit
    Leip, Eric
    Kelly, Virginia
    Turnbull, Kathleen
    Besson, Nadine
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [10] Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
    Swords, Ronan
    Mahalingam, Devalingam
    Padmanabhan, Swaminathan
    Carew, Jennifer
    Giles, Francis
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2009, 3 : 89 - 101
12345